Avelumab Alone or in Combination with Chemotherapy vs Chemotherapy Alone in Platinum-Resistant or Platinum-Refractory Ovarian Cancer (JAVELIN Ovarian 200): A Randomised, Open-Label, Phase 3 Study

Anlotinib in Combination with TQB2450 in Patients with Platinum-Resistant or Platinum-Refractory Ovarian Cancer (ACTION): A Multicenter, Single-Arm, Open-Label, Phase 1b Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3987490 ◽

2021 ◽

Author(s):

Chunyan Lan ◽

Jing Zhao ◽

Fan Yang ◽

Ying Xiong ◽

Rong Li ◽

...

Keyword(s):

Ovarian Cancer ◽

Open Label ◽

Platinum Resistant ◽

Open Label Phase ◽

Platinum Refractory ◽

Phase 1B

Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study

The Lancet Oncology ◽

10.1016/s1470-2045(21)00216-3 ◽

2021 ◽

Cited By ~ 1

Author(s):

Eric Pujade-Lauraine ◽

Keiichi Fujiwara ◽

Jonathan A Ledermann ◽

Amit M Oza ◽

Rebecca Kristeleit ◽

...

Keyword(s):

Ovarian Cancer ◽

Open Label ◽

Phase 3 ◽

Platinum Resistant ◽

Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL)

Gynecologic Oncology ◽

10.1016/j.ygyno.2021.08.032 ◽

2021 ◽

Author(s):

Stephanie Gaillard ◽

Ana Oaknin ◽

Isabelle Ray-Coquard ◽

Ignace Vergote ◽

Giovanni Scambia ◽

...

Keyword(s):

Ovarian Cancer ◽

Liposomal Doxorubicin ◽

Pegylated Liposomal Doxorubicin ◽

Open Label ◽

Phase 3 ◽

Randomized Controlled ◽

Platinum Resistant ◽

Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(15)70115-4 ◽

2015 ◽

Vol 16 (5) ◽

pp. 561-568 ◽

Cited By ~ 78

Author(s):

Sandro Pignata ◽

Domenica Lorusso ◽

Giovanni Scambia ◽

Daniela Sambataro ◽

Stefano Tamberi ◽

...

Keyword(s):

Ovarian Cancer ◽

Advanced Ovarian Cancer ◽

Weekly Paclitaxel ◽

Phase 2 ◽

Open Label ◽

Phase 2 Trial ◽

Platinum Resistant ◽

Open Label Phase ◽

Apatinib, a novel VEGFR inhibitor, combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer: A single-arm, open-label, phase 2 study.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.5515 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 5515-5515

Author(s):

Chunyan Lan ◽

Yin Wang ◽

Ying Xiong ◽

Judong Li ◽

Yanfang Li ◽

...

Keyword(s):

Ovarian Cancer ◽

Oral Etoposide ◽

Phase 2 ◽

Open Label ◽

Platinum Resistant ◽

Phase 2 Study ◽

Open Label Phase ◽

Platinum Refractory ◽

Vegfr Inhibitor

Avelumab Alone or in Combination With Chemotherapy Versus Chemotherapy Alone in Platinum-Resistant or Platinum-Refractory Ovarian Cancer (JAVELIN Ovarian 200): An Open-Label, Three-Arm, Randomised, Phase 3 Study

Obstetrical & Gynecological Survey ◽

10.1097/ogx.0000000000000980 ◽

2021 ◽

Vol 76 (11) ◽

pp. 673-675

Author(s):

Eric Pujade-Lauraine ◽

Keiichi Fujiwara ◽

Jonathan A. Ledermann ◽

Amit M. Oza ◽

Rebecca Kristeleit ◽

...

Keyword(s):

Ovarian Cancer ◽

Open Label ◽

Phase 3 ◽

Platinum Resistant ◽

Faculty Opinions recommendation of Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.737782327.793577733 ◽

2020 ◽

Author(s):

Diana English ◽

Andrea Buras

Keyword(s):

Ovarian Cancer ◽

Recurrent Ovarian Cancer ◽

Open Label ◽

Phase 3 ◽

The MEK Inhibitor in Low-Grade Serous Ovarian Cancer (MILO)/ENGOT-ov11 study: A multinational, randomized, open-label phase 3 study of binimetinib (MEK162) versus physician’s choice chemotherapy in patients with recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.tps5618 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. TPS5618-TPS5618

Author(s):

Bradley J. Monk ◽

Rachel N. Grisham ◽

Christian Marth ◽

Susana N. Banerjee ◽

Felix Hilpert ◽

...

Keyword(s):

Ovarian Cancer ◽

Fallopian Tube ◽

Mek Inhibitor ◽

Low Grade ◽

Serous Ovarian Cancer ◽

Open Label ◽

Phase 3 ◽

The MILO (MEK inhibitor in low-grade serous ovarian cancer)/ENGOT-ov11 study: A multinational, randomized, open-label phase 3 study of binimetinib (MEK162) versus physician’s choice chemotherapy in patients with recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.tps5610 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. TPS5610-TPS5610 ◽

Cited By ~ 4

Author(s):

Bradley J. Monk ◽

Rachel N. Grisham ◽

Christian Marth ◽

Susana N. Banerjee ◽

Felix Hilpert ◽

...

Keyword(s):

Ovarian Cancer ◽

Fallopian Tube ◽

Mek Inhibitor ◽

Low Grade ◽

Serous Ovarian Cancer ◽

Open Label ◽

Phase 3 ◽

5005 ORAL Randomized, multicenter, 2-dose-level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody catumaxomab (anti-EpCAM × anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(07)71177-1 ◽

2007 ◽

Vol 5 (4) ◽

pp. 312 ◽

Cited By ~ 1

Author(s):

S. Loibl ◽

J. Pfisterer ◽

P. Wimberger ◽

C. Kurzeder ◽

A. Du Bois ◽

...

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Cancer Patients ◽

Dose Level ◽

Bispecific Antibody ◽

Open Label ◽

Open Label Phase ◽